QGEN Healthcare

Qiagen N.V.

$50.38+0.06%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Diagnostics & Research
Country: Netherlands
Market cap: 10.4B USD
Enterprise value: 10.6B USD
Full-time employees: 5,500

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
About average: risk (debt, liquidity and share-price swings)risk

Ranks #141 of 1,157 healthcare companies (top 13%)

See how it ranks against its peers

Worth knowing

Investment surge. Capital spending 9.6% of revenue, up from 6.0% in 2022.
Qiagen is spending 9.6% of revenue on facilities and equipment, up from 6.0% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.
Profit is backed by cash. Free cash flow is 107% of reported profit.
Qiagen's free cash flow is 107% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.
Wide margins. Operating margin 22% (12 months to Dec 2025) vs a peer median of 7.1%.Operating margin 22% vs peers 7.1%.
Qiagen keeps 22% of revenue as operating profit, more than 84% of peers (median 7.1%).

StockQuotient Score

70/ 100

Oct 5 71 → Nov 4 70 (-1)

Valuation

Is the price right?

63/100

Moderate

3/3 inputs reported · High confidence

Since last year: No major changeValuation also moves with the share price every day.

Why

Stronger than most peers on:

▲ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield3.9%

SEC filings · 12 months to Dec 2025Reported value30% base weight · Z-score 1.63Sector median: 0.0148 · MAD: 0.0148

EBITDA yield5.8%

SEC filings · 12 months to Dec 2025Reported value50% base weight · Z-score 0.44Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield4.1%

SEC filings · 12 months to Dec 2025 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield34.6%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

87/100

Strong

3/3 inputs reported · High confidence

Since last year: ▲ Stronger

12-month revenue up 5.7%

Why

Stronger than most peers on:

▲ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth420.9%

SEC filings · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 9.28Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-0.8%

SEC filings · 3 years to Dec 2025Reported value33% base weight · Z-score -0.79Sector median: 0.0584 · MAD: 0.0840

Revenue growth5.7%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score -0.05Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

77/100

Moderate

3/3 inputs reported · High confidence

Since last year: ▲ Stronger

Operating margin rose 17.4 points to 22.3%

Why

Stronger than most peers on:

▲ Operating margin
▲ ROA
▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin22.3%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score 1.25Sector median: 0.0706 · MAD: 0.1217

Return on assets6.8%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score 0.95Sector median: 0.0166 · MAD: 0.0537

Return on invested capital8.0%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score 0.33Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin62.2%

SEC filings · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity11.2%

SEC filings · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last year: No major change

Why

Mixed versus peers:

▲ Current ratio
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.63

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.00Sector median: 0.6250 · MAD: 0.3380

Current ratio3.90×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.95Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.44×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.06Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Qiagen

Is Qiagen getting weaker?: Its latest SEC filing (Mar 20, 2026) got stronger: operating margin rose 17.4 points to 22.3%. Its overall score is unchanged at 70/100 since Oct 28, 2026.
How is Qiagen valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 63/100 against 1,393 healthcare peers. Earnings yield 3.9% vs a peer median of 1.5% (stronger than 70% of peers).Earnings yield 3.9% vs peers 1.5% (stronger than 70% of peers).
Is Qiagen growing?: Yes, faster than most of its peers. Growth scores 87/100 against 1,393 healthcare peers. Earnings per share growth 420.9% vs a peer median of 9.8% (stronger than 97% of peers).Earnings per share growth 420.9% vs peers 9.8% (stronger than 97% of peers). 3-year revenue growth -0.8% vs a peer median of 5.8% (weaker than 73% of peers).3-year revenue growth -0.8% vs peers 5.8% (weaker than 73% of peers).
How profitable is Qiagen?: More profitable than most of its peers. Profitability scores 77/100 against 1,393 healthcare peers. Operating margin 22.3% vs a peer median of 7.1% (stronger than 84% of peers).Operating margin 22.3% vs peers 7.1% (stronger than 84% of peers).
How risky is Qiagen?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 3.90× vs a peer median of 2.59× (stronger than 65% of peers).Current ratio 3.90× vs peers 2.59× (stronger than 65% of peers). Debt / equity 0.44× vs a peer median of 0.22× (weaker than 63% of peers).Debt / equity 0.44× vs peers 0.22× (weaker than 63% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Dec 31, 2025 · filed Mar 20, 2026 · compared with the year ended Dec 31, 2024

Got stronger

Operating margin rose 17.4 points to 22.3%

	Previous year	Latest year	Change
Revenue (12 months)	2.0B USD	2.1B USD	+5.7%
Net income (12 months)	83.6M USD	424.9M USD	+408.3%
Operating margin	4.9%	22.3%	+17.4 pts
Free cash flow (12 months)	506.4M USD	453.3M USD	−10.5%
Debt	1.4B USD	1.7B USD	+18.9%
Cash	663.6M USD	839.0M USD	+26.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	64.4%	64.7%	62.8%	48.9%	62.2%	▲ 13 pts
Operating margin	28.0%	24.8%	20.9%	4.9%	22.3%	▲ 17 pts
Net margin	22.8%	19.8%	17.4%	4.2%	20.3%	▲ 16 pts
Return on assets (ROA)	8.3%	6.7%	5.6%	1.5%	6.8%	▲ 5.3 pts
Return on equity (ROE)	16.6%	12.2%	9.0%	2.3%	11.2%	▲ 8.9 pts
Free cash flow margin	19.9%	27.4%	15.8%	25.6%	21.7%	▼ 3.9 pts
Current ratio	1.39×	2.46×	1.99×	1.88×	3.90×	▲ 107%
Quick ratio	1.17×	2.09×	1.62×	1.61×	3.31×	▲ 105%
Debt to equity	0.63×	0.54×	0.40×	0.39×	0.44×	▲ 12%
Interest coverage	11.57×	9.11×	7.68×	2.23×	14.01×	▲ 529%

QGEN price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

About average: risk (debt, liquidity and share-price swings)risk

Ranks #141 of 1,157 healthcare companies (top 13%)

See how it ranks against its peers

Worth knowing

Investment surge. Capital spending 9.6% of revenue, up from 6.0% in 2022.

Qiagen is spending 9.6% of revenue on facilities and equipment, up from 6.0% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Profit is backed by cash. Free cash flow is 107% of reported profit.

Qiagen's free cash flow is 107% of its reported profit, so its earnings are turning into cash it can reinvest, pay out or use to reduce debt.

Wide margins. Operating margin 22% (12 months to Dec 2025) vs a peer median of 7.1%.Operating margin 22% vs peers 7.1%.

Qiagen keeps 22% of revenue as operating profit, more than 84% of peers (median 7.1%).

Questions investors ask about Qiagen

Is Qiagen getting weaker?

Its latest SEC filing (Mar 20, 2026) got stronger: operating margin rose 17.4 points to 22.3%. Its overall score is unchanged at 70/100 since Oct 28, 2026.

How is Qiagen valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 63/100 against 1,393 healthcare peers. Earnings yield 3.9% vs a peer median of 1.5% (stronger than 70% of peers).Earnings yield 3.9% vs peers 1.5% (stronger than 70% of peers).

Is Qiagen growing?

Yes, faster than most of its peers. Growth scores 87/100 against 1,393 healthcare peers. Earnings per share growth 420.9% vs a peer median of 9.8% (stronger than 97% of peers).Earnings per share growth 420.9% vs peers 9.8% (stronger than 97% of peers). 3-year revenue growth -0.8% vs a peer median of 5.8% (weaker than 73% of peers).3-year revenue growth -0.8% vs peers 5.8% (weaker than 73% of peers).

How profitable is Qiagen?

More profitable than most of its peers. Profitability scores 77/100 against 1,393 healthcare peers. Operating margin 22.3% vs a peer median of 7.1% (stronger than 84% of peers).Operating margin 22.3% vs peers 7.1% (stronger than 84% of peers).

How risky is Qiagen?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 3.90× vs a peer median of 2.59× (stronger than 65% of peers).Current ratio 3.90× vs peers 2.59× (stronger than 65% of peers). Debt / equity 0.44× vs a peer median of 0.22× (weaker than 63% of peers).Debt / equity 0.44× vs peers 0.22× (weaker than 63% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Revenue (12 months)

2.0B USD

2.1B USD

+5.7%

Net income (12 months)

83.6M USD

424.9M USD

+408.3%

Operating margin

4.9%

22.3%

+17.4 pts

Free cash flow (12 months)

506.4M USD

453.3M USD

−10.5%

Debt

1.4B USD

1.7B USD

+18.9%

Cash

663.6M USD

839.0M USD

+26.4%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

64.4%

64.7%

62.8%

48.9%

62.2%

▲ 13 pts

Operating margin

28.0%

24.8%

20.9%

4.9%

22.3%

▲ 17 pts

Net margin

22.8%

19.8%

17.4%

4.2%

20.3%

▲ 16 pts

Return on assets (ROA)

8.3%

6.7%

5.6%

1.5%

6.8%

▲ 5.3 pts

Return on equity (ROE)

16.6%

12.2%

9.0%

2.3%

11.2%

▲ 8.9 pts

Free cash flow margin

19.9%

27.4%

15.8%

25.6%

21.7%

▼ 3.9 pts

Current ratio

1.39×

2.46×

1.99×

1.88×

3.90×

▲ 107%

Quick ratio

1.17×

2.09×

1.62×

1.61×

3.31×

▲ 105%

Debt to equity

0.63×

0.54×

0.40×

0.39×

0.44×

▲ 12%

Interest coverage

11.57×

9.11×

7.68×

2.23×

14.01×

▲ 529%